by Ilaria Colombo | 19 July 2024 | Women's Cancers
Compared to other tumor types, the development of HER2-targeted therapies for gynecological malignancies is lagging somewhat behind. Nevertheless, promising data have already been generated in the treatment of endometrial, cervical, and ovarian cancer.  © Freepik |...
by EMA Approval | 12 July 2024 | Urogenital, Women's Cancers
The European Union has recommended new treatment options for patients with primary advanced or recurrent endometrial cancer and metastatic urothelial carcinoma. Durvalumab and Olaparib have been endorsed for endometrial cancer based on positive trial results, while...
by EMA Approval | 20 June 2024 | Women's Cancers
Capivasertib, in combination with fulvestrant, has received approval from the European Union (EU) for treating adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer. This approval targets patients with specific...
by FDA Approval | 18 June 2024 | Women's Cancers
The Food and Drug Administration (FDA) has approved new treatments for endometrial cancer and Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (Ph-negative BCP ALL). These advancements promise to enhance therapeutic options and improve...
by Nadia Harbeck | 3 June 2024 | Women's Cancers
Nadia Harbeck, MD, PhD, stands out as an outstanding candidate for the ESMO presidency, distinguished by her remarkable professional achievements and inspirational commitment. She embodies a remarkable capacity to seamlessly manage the diverse responsibilities of...